Dashboard
1
High Management Efficiency with a high ROE of 60.39%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 22.81
3
Poor long term growth as Net Sales has grown by an annual rate of -6.11% and Operating profit at -8.51% over the last 5 years
4
With ROE of 65.53%, it has a Fair valuation with a 5.25 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
EUR 136 Million (Micro Cap)
8.00
NA
884.96%
-0.79
65.53%
5.25
Revenue and Profits:
Net Sales:
30 Million
(Quarterly Results - Mar 2022)
Net Profit:
7 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.16%
0%
8.16%
6 Months
19.77%
0%
19.77%
1 Year
25.44%
0%
25.44%
2 Years
30.46%
0%
30.46%
3 Years
32.92%
0%
32.92%
4 Years
10.13%
0%
10.13%
5 Years
46.21%
0%
46.21%
Naturhouse Health SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-6.11%
EBIT Growth (5y)
-8.51%
EBIT to Interest (avg)
22.81
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.62
Sales to Capital Employed (avg)
2.35
Tax Ratio
27.95%
Dividend Payout Ratio
49.24%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
106.85%
ROE (avg)
60.39%
Valuation key factors
Factor
Value
P/E Ratio
8
Industry P/E
Price to Book Value
5.25
EV to EBIT
5.19
EV to EBITDA
4.67
EV to Capital Employed
21.47
EV to Sales
1.55
PEG Ratio
0.09
Dividend Yield
884.96%
ROCE (Latest)
413.80%
ROE (Latest)
65.53%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'22 - YoY
Mar'22
Mar'21
Change(%)
Net Sales
30.30
14.60
107.53%
Operating Profit (PBDIT) excl Other Income
9.20
5.60
64.29%
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
6.60
3.60
83.33%
Operating Profit Margin (Excl OI)
265.10%
335.50%
-7.04%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2022 is 107.53% vs -12.57% in Mar 2021
Consolidated Net Profit
YoY Growth in quarter ended Mar 2022 is 83.33% vs 50.00% in Mar 2021
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
49.40
50.40
-1.98%
Operating Profit (PBDIT) excl Other Income
15.40
18.60
-17.20%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
9.90
11.20
-11.61%
Operating Profit Margin (Excl OI)
272.50%
323.10%
-5.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -1.98% vs -3.82% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -11.61% vs 16.67% in Dec 2023
About Naturhouse Health SA 
Naturhouse Health SA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






